Neuphoria Therapeutics Inc. - Common Stock (NEUP) Competitors $4.88 -0.17 (-3.37%) As of 02/21/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrends NEUP vs. COEP, SNYR, VRCA, GRCE, UBX, ANEB, PULM, PASG, ANVS, and CALCShould you be buying Neuphoria Therapeutics Inc. - Common Stock stock or one of its competitors? The main competitors of Neuphoria Therapeutics Inc. - Common Stock include Coeptis Therapeutics (COEP), Synergy CHC Corp. (Uplisting) (SNYR), Verrica Pharmaceuticals (VRCA), Grace Therapeutics (GRCE), Unity Biotechnology (UBX), Anebulo Pharmaceuticals (ANEB), Pulmatrix (PULM), Passage Bio (PASG), Annovis Bio (ANVS), and CalciMedica (CALC). These companies are all part of the "pharmaceutical products" industry. Neuphoria Therapeutics Inc. - Common Stock vs. Coeptis Therapeutics Synergy CHC Corp. (Uplisting) Verrica Pharmaceuticals Grace Therapeutics Unity Biotechnology Anebulo Pharmaceuticals Pulmatrix Passage Bio Annovis Bio CalciMedica Neuphoria Therapeutics Inc. - Common Stock (NASDAQ:NEUP) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, community ranking, valuation and media sentiment. Is NEUP or COEP more profitable? Neuphoria Therapeutics Inc. - Common Stock's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics Inc. - Common StockN/A N/A N/A Coeptis Therapeutics N/A -1,094.50%-219.97% Does the media favor NEUP or COEP? In the previous week, Coeptis Therapeutics had 7 more articles in the media than Neuphoria Therapeutics Inc. - Common Stock. MarketBeat recorded 7 mentions for Coeptis Therapeutics and 0 mentions for Neuphoria Therapeutics Inc. - Common Stock. Neuphoria Therapeutics Inc. - Common Stock's average media sentiment score of 0.00 equaled Coeptis Therapeutics'average media sentiment score. Company Overall Sentiment Neuphoria Therapeutics Inc. - Common Stock Neutral Coeptis Therapeutics Neutral Do analysts rate NEUP or COEP? Neuphoria Therapeutics Inc. - Common Stock presently has a consensus price target of $21.00, suggesting a potential upside of 330.33%. Given Neuphoria Therapeutics Inc. - Common Stock's stronger consensus rating and higher possible upside, equities analysts clearly believe Neuphoria Therapeutics Inc. - Common Stock is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics Inc. - Common Stock 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Coeptis Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community prefer NEUP or COEP? Coeptis Therapeutics received 4 more outperform votes than Neuphoria Therapeutics Inc. - Common Stock when rated by MarketBeat users. However, 100.00% of users gave Neuphoria Therapeutics Inc. - Common Stock an outperform vote while only 83.33% of users gave Coeptis Therapeutics an outperform vote. CompanyUnderperformOutperformNeuphoria Therapeutics Inc. - Common StockOutperform Votes1100.00% Underperform VotesNo VotesCoeptis TherapeuticsOutperform Votes583.33% Underperform Votes116.67% Do insiders and institutionals believe in NEUP or COEP? 15.9% of Neuphoria Therapeutics Inc. - Common Stock shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 0.7% of Neuphoria Therapeutics Inc. - Common Stock shares are owned by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has preferable earnings and valuation, NEUP or COEP? Neuphoria Therapeutics Inc. - Common Stock has higher revenue and earnings than Coeptis Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuphoria Therapeutics Inc. - Common Stock$10K858.88-$15.49MN/AN/ACoeptis TherapeuticsN/AN/A-$21.27M-$5.80-1.81 Which has more volatility & risk, NEUP or COEP? Neuphoria Therapeutics Inc. - Common Stock has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.82, meaning that its stock price is 182% less volatile than the S&P 500. SummaryNeuphoria Therapeutics Inc. - Common Stock beats Coeptis Therapeutics on 10 of the 13 factors compared between the two stocks. Get Neuphoria Therapeutics Inc. - Common Stock News Delivered to You Automatically Sign up to receive the latest news and ratings for NEUP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEUP vs. The Competition Export to ExcelMetricNeuphoria Therapeutics Inc. - Common StockPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.87M$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.4725.4719.00Price / Sales858.88306.08447.5876.30Price / CashN/A65.6738.0134.83Price / Book0.626.717.644.62Net Income-$15.49M$138.33M$3.18B$245.85M7 Day Performance-1.21%-2.61%-1.99%-2.68%1 Month Performance44.38%-2.32%-0.42%-2.19%1 Year PerformanceN/A-5.31%16.51%12.84% Neuphoria Therapeutics Inc. - Common Stock Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEUPNeuphoria Therapeutics Inc. - Common Stock1.2883 of 5 stars$4.88-3.4%$21.00+330.3%N/A$8.87M$10,000.000.00N/AEarnings ReportCOEPCoeptis Therapeutics0.546 of 5 stars$10.48-5.0%N/A+7.5%$33.95MN/A-1.812News CoverageSNYRSynergy CHC Corp. (Uplisting)N/A$3.87-0.3%$10.00+158.4%N/A$33.67MN/A0.0040Gap UpVRCAVerrica Pharmaceuticals3.9342 of 5 stars$0.74-0.8%$9.50+1,190.6%-85.2%$33.57M$5.12M-0.4040Gap UpGRCEGrace Therapeutics2.6 of 5 stars$3.29-2.9%$12.00+264.7%N/A$33.36MN/A-2.84N/AAnalyst ForecastAnalyst RevisionNews CoverageGap DownUBXUnity Biotechnology3.8575 of 5 stars$1.94-5.4%$7.33+278.0%+10.9%$32.69M$240,000.00-1.4860ANEBAnebulo Pharmaceuticals3.2389 of 5 stars$1.26-11.0%$8.00+534.9%-58.0%$32.67MN/A-4.504Earnings ReportNews CoveragePULMPulmatrix0.0789 of 5 stars$8.92-1.0%N/A+404.0%$32.56M$7.30M-3.3820PASGPassage Bio2.5467 of 5 stars$0.52-4.6%$7.75+1,376.8%-57.7%$32.42MN/A-0.45130News CoverageANVSAnnovis Bio2.0964 of 5 stars$2.13-4.3%$31.40+1,371.4%-79.0%$31.75MN/A-0.483CALCCalciMedica2.5967 of 5 stars$2.35-3.7%$18.00+666.0%-47.7%$31.68MN/A-2.1830Gap Down Related Companies and Tools Related Companies COEP Competitors SNYR Competitors VRCA Competitors GRCE Competitors UBX Competitors ANEB Competitors PULM Competitors PASG Competitors ANVS Competitors CALC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NEUP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuphoria Therapeutics Inc. - Common Stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuphoria Therapeutics Inc. - Common Stock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
